A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Clinical trial NCT06920043 · RECRUITING

Trial details

NCT number: NCT06920043
Sponsor: GlaxoSmithKline
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metabolic Dysfunction-Associated Steatohepatitis Non-alcoholic Fatty Liver Disease

Start date: 2025-04-09
Primary completion: 2028-07-10
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.